SciELO - Scientific Electronic Library Online

vol.78 suppl.1 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Medicina (Buenos Aires)

Print version ISSN 0025-7680On-line version ISSN 1669-9106


DUBROVSKY, Alberto et al. Consenso argentino sobre enfermedad de Pompe de inicio tardío. Medicina (B. Aires) [online]. 2018, vol.78, suppl.1, pp.1-23. ISSN 0025-7680.

Pompe’s disease (PD) is an infrequent metabolic autosomic recessive disorder produced by the lack or deficiency of the acid alpha-glucosidase lysosomal enzyme in tissues of involved individuals. Delayed-onset PD is considered whenever symptoms onset start after one year of age. We present an update of the recommendations for the management of delayed-onset PD, taking as reference the guidelines from the Argentine Consensus for diagnosis, treatment and follow-up of PD published in 2013. The present consensus gathered several experts in PD in the areas of internal medicine, laboratory diagnosis, neuropathology, pulmonology, nutrition, neurology, metabolic and neuromuscular disorders as well as rehabilitation to perform an update of the literature of delayed-onset PD, with special attention on relevant information published within the last 4 years. The entire working group approved the final version of the consensus. Each participant provided a declaration of conflict of interest. As a result, it is an update of the previous Argentine PD Consensus with focus on the delayed-onset presentation of the disease. Being such infrequent disorder, available data were rather limited and thus, the recommendations represent expert opinions.

Keywords : Alfa-glucosidase; Consensus; Acid lisosomal maltase deficiency; Pompe’s disease; Type II glycogenosis; Enzyme replacement therapy.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License